Skip to main content
All lobbying filings

NATIONAL MULTIPLE SCLEROSIS SOCIETY

Lobbying for NATIONAL MULTIPLE SCLEROSIS SOCIETY

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $83,979.00 expenses · posted Apr 21, 2025

Official filing document

 Bills named in this filing 7
  • HR 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025
  • HCONRES 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • S 925
    Credit for Caring Act of 2025
  • HR 2036
    Credit for Caring Act of 2025
  • HR 2320
    Mobility Means Freedom Tax Credit Act
  • S 830
    Lifespan Respite Care Reauthorization Act of 2025
  • HR 2560
    Lifespan Respite Care Reauthorization Act of 2025
 Lobbying activity 4
Budget/Appropriations

H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. Supporting the following funding levels in FY25 appropriations bills: $51.303 billion for the National Institutes of Health (NIH) for fiscal year (FY) 2026. Supporting established funding levels for Medicare and Medicaid and protection of Medicaid's current financing structure. DoD- Working to restore funding for the Congressionally Directed MS Research Program which was zeroed out in the last Continuing Resolution. Specifically $22 million for the MS Research Program and $6.54 Million for Veterans Affairs Centers of Excellence.

Health Issues

S. 925 - Credit for Caring Act of 2025 H.R. 2036 - Credit for Caring Act of 2025 H.R. 2320 - The Mobility Means Freedom Tax Credit Act S. 830 - Lifespan Respite Care Reauthorization Act of 2025 H.R. 2560 - Lifespan Respite Care Reauthorization Act of 2025 H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. Commented and proposed recommendations on FDA's Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products as well as FDA's Artificial Intelligence-Enabled Device Software Functions.

Medicare/Medicaid

H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. Joined with coalition partners to request CMS to expand coverage for anti-obesity medications. In January commented on CMS's Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly. In April provided recommendations on CMS's Patient Protection and Affordable Care Act; Marketplace Integrity and Affordability.

Medical/Disease Research/Clinical Labs

H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem